Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease-Reference-Cited by-同舟云学术

Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease

Published:2019-02 Issue:2 Volume:143 Page:799-803.e2
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Cahill Katherine N.,Murphy Katherine,Singer Joseph,Israel Elliot,Boyce Joshua A.,Laidlaw Tanya M.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference8 articles.

1. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges;White;Ann Allergy Asthma Immunol,2006

2. Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics;Stevenson;Ann Allergy Asthma Immunol,2000

3. Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease;Cahill;J Allergy Clin Immunol,2015

4. Tryptase and histamine release during aspirin-induced respiratory reactions;Bosso;J Allergy Clin Immunol,1991

5. A trial of P2Y12 receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease;Laidlaw;J Allergy Clin Immunol,2018

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mast Cells in Aspirin-Exacerbated Respiratory Disease;Current Allergy and Asthma Reports;2024-01-13

2. Nasal Polyposis and Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease;Nasal Polyposis and its Management;2024

3. Management of Aspirin-Exacerbated Respiratory Disease;Otolaryngologic Clinics of North America;2023-10

4. Can we apply biomarkers in the management of non-steroidal anti-inflammatory drug exacerbated respiratory disease?;Exploration of Asthma & Allergy;2023-08-24

5. Mechanistic and clinical updates in AERD: 2021-2022;Journal of Allergy and Clinical Immunology;2023-06